Capsule Summary Slidesets


Share

Program Content

Activities

  • TALAPRO-2
    TALAPRO-2: Phase III Trial of First-line Talazoparib + Enzalutamide in mCRPC
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 21, 2023

    Expires: February 20, 2024

  • MAGNITUDE Update: Niraparib in mCRPC
    MAGNITUDE: Update of Phase III Trial of First-line Niraparib With Abiraterone Acetate and Prednisone in mCRPC With HRR Gene Alterations
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 21, 2023

    Expires: February 20, 2024

  • TRITON3: Rucaparib in mCRPC
    TRITON3: Phase III Trial of Rucaparib vs Physician’s Choice Therapy in Metastatic CRPC With BRCA or ATM Alterations
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 21, 2023

    Expires: February 20, 2024

  • ARASENS Post Hoc Analysis
    ARASENS: Post Hoc Analysis of Outcomes by Disease Volume and Risk With Darolutamide vs Placebo in Combination With ADT + Docetaxel in Metastatic HSPC
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2023

    Expires: February 21, 2024

  • Neoadjuvant Pembrolizumab + CT in MIUC
    Phase Ib/II Study of Neoadjuvant Chemotherapy + Pembrolizumab for Muscle-Invasive Urothelial Cancer
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2023

    Expires: February 21, 2024

  • TROPHY-U-01 Cohort 2
    TROPHY-U-01 Cohort 2: Sacituzumab Govitecan After Checkpoint Inhibition in Platinum-Ineligible Metastatic Urothelial Cancer
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2023

    Expires: February 21, 2024

  • CheckMate 9ER 3-Yr Follow-up
    CheckMate 9ER: 3-Yr Follow-up of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2023

    Expires: February 21, 2024

  • PROpel Final Prespecified OS Analysis
    Final Prespecified OS Analysis of PROpel: Phase III Trial of First-line Abiraterone + Olaparib vs Abiraterone + Placebo in Metastatic CRPC
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2023

    Expires: February 21, 2024

  • PACE-A
    PACE-A: Phase III Trial of Stereotactic Body Radiotherapy vs Surgery for Localized Prostate Cancer
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 24, 2023

    Expires: February 23, 2024

  • CaboPoint
    CaboPoint: Phase II Trial of Second-line Cabozantinib Following Checkpoint Inhibitor–Based Combination Therapy for Advanced RCC
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 24, 2023

    Expires: February 23, 2024

  • KEYNOTE-057 Cohort B
    KEYNOTE-057 Cohort B: Phase II Trial of Pembrolizumab Monotherapy in Patients With High-Risk Papillary NMIBC
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 24, 2023

    Expires: February 23, 2024

  • JAVELIN Bladder 100
    JAVELIN Bladder 100: Long-term Follow-up of Avelumab Maintenance for Advanced Urothelial Cancer by First-line Chemotherapy Regimen
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2023

    Expires: February 26, 2024

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.